Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High-dose Interleukin-2”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT02306954
What this trial is testing

Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer

Who this might be right for
Renal Cell Carcinoma
Providence Health & Services 84
Not applicableStudy completedNCT00912418
What this trial is testing

Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma

Who this might be right for
Melanoma
Craig L Slingluff, Jr 14
Testing effectiveness (Phase 2)Looking for participantsNCT06630611
What this trial is testing

Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)

Who this might be right for
MelanomaNon Small Cell Lung CancerCervical Cancer
Vall d'Hebron Institute of Oncology 40
Testing effectiveness (Phase 2)Ended earlyNCT01874119
What this trial is testing

Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma

Who this might be right for
Chemotherapy-induced Nausea and Vomiting
St. Louis University 13
Testing effectiveness (Phase 2)UnknownNCT00080977
What this trial is testing

High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2

Who this might be right for
Kidney Cancer
Blumenthal Cancer Center at Carolinas Medical Center